Purpose: Benign prostatic hyperplasia (BPH) is strongly associated with obesity and prostatic tissue inflammation, but the molecular underpinning of this relationship is not known. Here, we examined the association between urine levels of chemokines/ adipokines with histological markers of prostate inflammation, obesity, and lower urinary tract symptoms LUTS in BPH patients.
| INTRODUCTION

Accumulating evidence from large clinical studies including Medical Therapy Of Prostatic Symptoms (MTOPS) and Reduction by
Dutasteride of Prostate Cancer Events (REDUCE) strongly suggests a role for prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). 1 The role of inflammation in BPH was further supported by the finding of an inverse association of LUTS with daily use of non-steroidal anti-inflammatory drugs in the Olmsted County Study of Aging. 2 Healthy prostate is an immunocompetent organ, populated with a small number of stromal and intraepithelial T and B lymphocytes. 3 Intra-prostatic lymphocytic infiltration in prostate tissue is a sign of inflammation, 4 which is phenotyped by grade, extent 5 and the density of CD3+ and CD20+ staining. Intra prostatic infiltration in transition zone of prostate 6 was positively associated with symptom scores of LUTS, 6 but inflammation in peripheral zone was not strongly associated with LUTS in a recent study. 7 Since chemokine expression temporally precedes the intraprostatic infiltration, 8 chemokines have been studied as molecular signatures of inflammation in prostate tissue 4 and in expressed prostatic secretions. 9 Epidemiological evidence suggests that prostatic inflammation associated with BPH is most likely initiated in response to metabolic stress signals, 10 which may explain a modest overall increased prevalence of BPH/LUTS in obese subjects. 11, 12 The present study seeks to evaluate whether urinary chemokines can reflect the clinical attributes of BPH/LUTS patients. The selection of the chemokines for the present study was based on the known role of following chemokines CXCL-1, CXCL-8, CXCL-10, CCL2, CCL3, and CCL5 in the chemoattraction of CD3+ and CD20+ lymphocytes [13] [14] [15] [16] [17] [18] and the reports on detection of other included proteins in the prostate tissue or biofluids of BPH patients or patients suffering from LUTS. 19, 20 2 | PATIENTS AND METHODS
| Study population
Participants were enrolled as a part of the Nashville Men's Health 
| Immune cell infiltration
We measured CD3, a marker of T cell infiltration, and CD20, a marker CXC chemokines (CXCL-1, CXCL-8, CXCL-10), CC chemokines (CCL2, CCL3, CCL5), sIL-1ra, platelet derived growth factor −BB (PDGF-BB), interleukin IL-6, IL-17, and sCD40L were analyzed using Luminex™ xMAP® technology.
| Statistical analysis
Patient characteristics were summarized with median and quartiles for continuous variables. Urine was available for analysis from 207 study participants and tissue inflammation scores were available from 107 participants. The number (n) varies across biomarker measures due to differences in assay failure rate across chemokines ( 3 | RESULTS
| Clinical characteristics
Quartile distribution of the clinical characteristics in study participants is summarized in Table 1 PSA, and AUA-SI were 49 mLs, 5 ng/mL, and 9, respectively. Table 2 summarizes the distribution and the considerable variability in the detection of eleven chemokines. The CCL2 and sIL-1ra were present above the assay limit in 89% of the enrolled patients and similar percentage of subjects showed detectable levels of CXCL-1, CXCL-8, and CXCL-10. In contrast, CCL5 and PDGF-BB were detectable in approximately one-half of participants, while levels of CCL3, IL-6, sCD40L, and IL-17 in urine were consistently low and below assay limit in a majority of patients likely due to degradation during storage period of 3-6 years prior to analysis.
| Urine levels of chemokines
| Association of urine levels with obesity measures
We first considered the potential interaction between obesity and urine levels of different chemokines and found that only sIL-1Ra was significantly associated ( respectively. After controlling for age and BPH treatment on log transformed sIL-1RA values, β coefficients from regression models were calculated to assess an overall effect estimate. The β coefficients for BMI (P = 0.02), waist circumference (P < 0.01) and waist hip ratio (P = 0.01)
were 0.04, 0.016, and 3, respectively. Stratification of BPH patients on the basis of obesity parameter (Table 3) found that urine levels of sIL-1RA were elevated by 47.5 pg/mL in 65 BPH patients with BMI >30
(P < 0.005). Likewise, urine levels of sIL-1Ra were nearly doubled in BPH patients with waist circumference larger than 104 cm (n = 107; P < 0.001) and those with higher waist-hip ratio (n = 105; P < 0.004).
Furthermore, statins, non-steroidal anti-inflammatory drugs (NSAIDs) or medications for hypertension were not associated with the adjusted sIL1Ra levels. The findings with regard to the association of urinary sIL-1Ra levels with obesity measures are significant after adjustment of P values for multiple testing by the FDR approach.
| Prostate tissue immune cell infiltration and urine chemokines
The infiltration of T and B cells in prostate biopsy was scored by staining of CD3 and CD20, respectively. The association between urine levels of chemokines within each participant was assessed with the local region of tissue with the maximal staining (Tables 4 and 5 ) and the mean levels of staining across all tissues. Urine levels of CCL5 after adjustment for age and treatment showed a marginal inverse association with maximal CD3 expression (β = −0.64, P = 0.054, n = 89) in prostate biopsy (Table 4 and Figure 2B ). None of the other chemokines were associated with maximal CD3 expression or with mean CD3 expression (data not shown). Only the urine levels of CCL3
were significantly associated with maximal CD20 staining (β = 2.93, P = 0.02; Table 5 ) and marginally associated with mean CD20 staining (β = 0.16, P = 0.09) (data not shown). These findings require further confirmation, because tissue inflammatory scores were only available for a quarter of 60 patients with urine levels of CCL3 above the detection limit. The association of CCL5 and CCL3 with CD3 and CD20, holds biological significance because CCL5 and CCL3 are primarily chemotactic for T-lymphocytes. After adjustment to age, 
| Association of urine levels with symptom scores
We next investigated the relationship between urine levels of chemokines and the symptom scores. Regression models using AUA-SI scores as the response and log-transformed chemokines as the explanatory response, found no significant association. Although, a marginal inverse association was notable between AUA-SI scores (β = −1.25, P = 0.076, n = 103) and sCD40L levels in urine ( Figure 2C ).
| DISCUSSION
Present study demonstrated that chemokines measured non-invasively in urine can reflect on the relationship of BPH/LUTS with obesity measures and prostatic inflammation. This current study restricted only to BPH patients negative for prostate cancer, as determined by prostate biopsy, found that increasing urine levels of CXCL-10, CCL5, and CCL3 were marginally associated with the extent of inflammation and greater intensity of CD3 and CD20 lymphocytic infiltration in prostate tissue. Previous studies have reported that urine levels of CXCL-10, CCL3, and CCL5 in healthy male asymptomatic control subjects are either undetectable or below the median values of BPH subjects reported here and elsewhere. 20, 22 One of the predisposing factor for BPH is the metabolic syndrome, 10 whose key determinant is the increased centralized deposition of adipose tissue. We found a broad and robust relationship between a key measure of centralized adiposity called waist-hip ratio and increased urine levels of sIL-1Ra. The source elevated sIL-1Ra in the urine of obese BPH patients is presumed to be elevated serum levels of sIL-1Ra, because serum levels of sIL-1ra were reported to be elevated sevenfold in morbidly obese men. 23 Besides, median urine levels of sIL-1Ra measured here in overweight or obese men with BPH were comparable to the published levels of sIL-1Ra in serum of lean men, 23, 24 which lend support to the suggestion that serum elevation of sIL-1Ra precedes the elevation in urine. The larger sample size of this study was able to reproduce the association of sIL-1Ra in urine with obesity measures of BMI, waist circumference and waist-hip ratio, found earlier in a pilot study. 19 Therefore, sIL-1Ra is the key molecular correlate for the obesity or greater body size of BPH patients 23, 24 , which is detectable in both serum and urine.
The cross-sectional study design used here is limited in determining temporal relationships between outcomes and hence future studies in this direction need to perform simultaneous longitudinal measurement of serum and urine specimens of same patients to investigate whether the elevation of sIL-1Ra in serum precedes the urinary elevation of sIL-1Ra in BPH patients. Besides, sIL1Ra, several other adipokines such as leptin can also be potential molecular correlate of greater body size in BPH patients. A significant association between serum levels of leptin and prostate enlargement was recently reported from serum analysis of another cohort of this dataset.
11
Stromal enlargement is the predominant histologic feature of BPH/LUTS and the CC chemokine CCL2 primarily released from stroma 13 was easily detectable in ∼90% of enrolled patients of our study. Other members of CC chemokine family namely CCL5 and CCL3
are chemotactic for the infiltration of CD3 + T lymphocytes and CD20 B lymphocytes, respectively. 14 We did not see a strong or significant relationship between CD3 or CD20 immune cell infiltration and the chemokine levels in urine for a large majority of BPH patients.
Intriguingly, the maximal density of CD3 + cells in prostate biopsy had an inverse association with the CCL5 levels measured in urine of BPH patients. The inverse association is intriguing considering that maximal CD3 staining in biopsy of BPH patients showed an inverse association with prostate volume in another cohort of this large dataset. 11 Besides, urine levels of CCL5 measured here in BPH patients were thousand fold lower than the serum levels reported in BPH patients, 15 that study however did not study the density of CD3 + cells in prostate biopsy of BPH patients. Basic research reported recently that androgen deprivation 17 upregulates CCL5 expression in prostatic epithelium, which is likely to be released into serum from prostate instead of urine.
Therefore, future studies need to concurrently investigate the serum and urine levels of CCL5 in BPH patients treated with NSAIDS and androgen deprivation therapy to understand the inverse association of urinary CCL5 with maximal CD3 density.
Tissue inflammation in biopsy specimens of BPH patient was scored by grade and extent to capture the total inflammatory effect FIGURE 1 (A) Scatter plot of unadjusted sIL-1RA levels in urine against waist-hip ratio (Panel A) BMI (Panel B) and waist circumference (Panel C). The association of unadjusted urine levels of sIL-1RA with waist-hip ratio, BMI and waist circumference was statistically significant with spearman correlation coefficient r s of 0.19 (P = 0.004), 0.15 (P = 0.02), and 0.2 (P = 0.003), respectively, as shown in panel A, B, and C. Linear regression modelling of sIL-1RA levels adjusted for age and BPH treatment determined β coefficient of 3 for waist hip ratio (P = 0.01) and 0.04 and 0.016 for BMI (P = 0.02) and waist circumference (P < 0.01), respectively Urine levels of sIL-1RA were significantly elevated in obese BPH patients with BMI >30 (n = 65; P < 0.005), having waist circumference larger than 104 cm (n = 107; P < 0.001), and waist-hip ratio greater than 1.02 (n = 105; P < 0.005). Urine levels of CCL3 were significantly associated with maximal CD20 expression. *Linear regression modelling employed CD20 as the response and the log transformed urinary chemokine as the primary covariate to calculate β coefficient adjusted for age and BPH treatment OAB patients relative to healthy controls. 28 Since, most of the men included in this study had incidental BPH with mild to moderate LUTS, future comparative studies need to be performed in symptomatic BPH and age matched asymptomatic healthy patients.
Chemokines primarily produced in stroma (CCL2) 16 fold lower than serum levels of CCL2 and several thousand fold lower than the serum CCL5 levels in BPH patients. 15 Comparison of the median urine levels for CC chemokines, CCL2 and CCL5 in BPH patients with the serum levels of respective chemokines reported in BPH patients 15 suggest preferential secretion of only CCL2 and not CCL5 from prostate into urine. The thousand fold higher serum levels of CCL5 15 reported in BPH patients compared to very low urine levels measured here suggests that CCL% is not directly secreted from prostate into urine.
Anatomic continuity of prostate with urethra facilitates the preferential drainage of overexpressed chemokines in prostate via shedding and budding of micro and multivesicular bodies from plasma membrane. 29 Urine is therefore biased towards detection of proteins that are overexpressed in prostate tissue such as CCL2 30 and PSA, 31 which are then secreted into detectable levels urine. In fact, 100 fold higher levels of PSA 31 in urine over serum are commensurate with direct secretion from prostate into urine instead of increased excretion of a 26 kDa protein 32 from a properly functioning kidney of BPH patients. However, urine may not be appropriate for the detection of CCL5 secreted from the prostate. Preferential drainage from prostate into urine may explain the relatively higher median urine levels of CXC chemokines, CXCL-1, CXCL-8, 33 and CXCL-10 18 in BPH patients compared to the reported serum levels of respective chemokines in BPH patients. 15 Our earlier study on female interstitial cystitis patients found significant association between chemokine levels measured in urine and the chemokine levels measured in respective bladder punch biopsy. 34 Considering that prostate biopsy is sensitive to sampling error, a urinary marker would avoid inflammation induced by the biopsy procedure and may represent inflammation in prostate tissue beyond the selected biopsy selection site. Since some of the study participant were taking medications, we controlled for the BPH treatment throughout the main analysis and the analyses stratified by BPH treatment status did not suggest an effect.
| CONCLUSIONS
Strong association of sIL-1Ra in urine with greater body size support it as a major molecular correlate of obesity in urine of BPH patients.
Increased urine levels of CXCL-10, CCL5 and CCL3 were marginally associated with the scores for prostate tissue inflammation and lymphocytic infiltration. Overall, urinary chemokines can non-invasively inform about the molecular underpinning of BPH/LUTS with obesity and prostatic inflammation.
